STAT+: AACR Highlights on Chinese Biotech and Oncology Communications

22 Apr 20264 min read0 viewsVerified Feed

GIST

You’re reading the web version of STAT’s popup newsletter, AACR in 30 seconds, your guide to what’s happening at the American Association of Cancer Researchers’ annual meeting. This is the last edition of our pop-up newsletter.

We hope you’ve learned as much as we have. If you’re not already a STAT+ subscriber, consider it!

There’s currently a  60% off promotion  on annual subscriptions. In the meantime, thanks for joining us.

Overcoming resistance and RevMed’s next drug? In case you missed it, Revolution Medicines’ sessions yesterday were jam-packed with conference attendees.

While most of the media coverage focused on the daraxonrasib in frontline pancreatic cancer data, the company also revealed some activity in a new compound, RM-055. CEO Mark Goldsmith described it as being part of a new class of “catalytic inhibitors,” since it can slice off a phosphate from GTP-RAS, or the “on” form of RAS, and turn the protein off.

Clinical Editorial

Context and setting

This brief piece is the final edition of STAT’s pop-up AACR newsletter, offering highlights from the American Association for Cancer Research annual meeting.

It is a short news item meant to signal a lead topic and point readers to STAT+ for fuller coverage.

Promotional subscription language is included in the source.

Primary signal — Revolution Medicines presentations

Revolution Medicines hosted well-attended sessions at the meeting.
Media attention concentrated on data for daraxonrasib in frontline pancreatic cancer.
The company also disclosed preliminary activity for a different compound, RM-055.

Mechanism and proposed novelty of RM-055

Company leadership described RM-055 as belonging to what they termed a new class of “catalytic inhibitors.”
The purported mechanism is removal of a phosphate from GTP-bound RAS (the active form), thereby inactivating the protein.
This catalytic action is presented as enabling a single molecule to inactivate multiple RAS proteins.

Rationale and perceived advantage

The source frames tumor resistance to RAS inhibitors as sometimes driven by amplification of mutant RAS, which can overwhelm inhibitors by increasing the oncoprotein quantity.
RM-055’s catalytic inactivation of multiple mutant RAS proteins was presented by the company as a potential way to address that resistance mechanism.

Data and limitations reported in the source

The source reports “some activity” for RM-055 but does not provide quantitative efficacy, safety, trial design details, patient population, or regulatory status.
No independent corroboration, peer-reviewed data, or specific outcome measures were provided in the item.